PTC Therapeutics Inc. (PTCT) presented interim data from Part 1 of the FIREFISH study of risdiplam in babies with Type 1 Spinal Muscular Atrophy, at the SMA Researcher Meeting over the weekend.
from RTT - Before the Bell https://ift.tt/2tglOvO
via IFTTT
No comments:
Post a Comment